A. Zhang

Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)

S Tagawa, O Sartor, J M Piulats, F Saad et autres

Ziel/Aim: ADT+androgen receptor pathway inhibitor (ARPI) is a standard of care for mHSPC but outcomes remain suboptimal. PSMAddition (NCT04720157) evaluates [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) combined with ADT+ARPI in PSMA+mHSPC. Methodik/Methods: Eligible adults had treatment-naïve/minimally treated (≤45 days) mHSPC and≥1 PSMA+metastatic …

us, es, ca, fr, gb, at, de, kr, tw, ch (code pays fourni par la source)

Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer

Aslı D. Munzur, Cameron Herberts, Edmond M. Kwan, Louise Emmett et autres

PURPOSE: Clonal hematopoiesis (CH) is a precursor state linked to risk of hematologic neoplasms and may be exacerbated by radiation exposure. We aimed to compare CH prevalence after the new radioligand therapy 177Lu-PSMA-617 versus the alternative standard-of-care cabazitaxel chemotherapy in metastatic castration-resistant …

ca, gb, us, au, nz (code pays fourni par la source)

LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)

S.T. Tagawa, O. Sartor, J.M. Piulats, F. Saad et autres

us, gb, es, ca, fr, at, de, kr, tw, ch (code pays fourni par la source)

35 (PB023): A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301)

A. Zhang, V. Boni, Adrienne R. Hanson, Claudia La Mantia et autres

72 (PB060): TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations

Y. Loriot, A. Zhang, Aaron R. Hansen, Charlene Mantia et autres

246P Impact of renal impairment on first-line treatment in metastatic urothelial cancer

S. Wakeling, Andrisha Jade Inderjeeth, A.J. Weickhardt, James Lynam et autres

au (code pays fourni par la source)

1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)

Craig Gedye, Carole A. Harris, Martin R. Stockler, Michelle Frances Morris et autres

au, us (code pays fourni par la source)

1739P Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

A.J. Weickhardt, F. Foroudi, J. Xie, K. Kanojia et autres

au (code pays fourni par la source)